Unknown

Dataset Information

0

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.


ABSTRACT: BACKGROUND:Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal meningitis if untreated. The progression and timing from asymptomatic infection to cryptococcal meningitis is unclear. We describe a subpopulation of individuals with neurologic symptomatic cryptococcal antigenemia but negative cerebral spinal fluid (CSF) studies. METHODS:We evaluated 1201 human immunodeficiency virus-seropositive individuals hospitalized with suspected meningitis in Kampala and Mbarara, Uganda. Baseline characteristics and clinical outcomes of participants with neurologic-symptomatic cryptococcal antigenemia and negative CSF cryptococcal antigen (CrAg) were compared to participants with confirmed CSF CrAg+ cryptococcal meningitis. Additional CSF testing included microscopy, fungal culture, bacterial culture, tuberculosis culture, multiplex FilmArray polymerase chain reaction (PCR; Biofire), and Xpert MTB/Rif. RESULTS:We found 56% (671/1201) of participants had confirmed CSF CrAg+ cryptococcal meningitis and 4% (54/1201) had neurologic symptomatic cryptococcal antigenemia with negative CSF CrAg. Of those with negative CSF CrAg, 9% (5/54) had Cryptococcus isolated on CSF culture (n = 3) or PCR (n = 2) and 11% (6/54) had confirmed tuberculous meningitis. CSF CrAg-negative patients had lower proportions with CSF pleocytosis (16% vs 26% with ?5 white cells/?L) and CSF opening pressure >200 mmH2O (16% vs 71%) compared with CSF CrAg-positive patients. No cases of bacterial or viral meningitis were detected by CSF PCR or culture. In-hospital mortality was similar between symptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%; P = .91). CONCLUSIONS:Cryptococcal antigenemia with meningitis symptoms was the third most common meningitis etiology. We postulate this is early cryptococcal meningoencephalitis. Fluconazole monotherapy was suboptimal despite Cryptococcus-negative CSF. Further studies are warranted to understand the clinical course and optimal management of this distinct entity. CLINICAL TRIALS REGISTRATION:NCT01802385.

SUBMITTER: Ssebambulidde K 

PROVIDER: S-EPMC6541705 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Ssebambulidde Kenneth K   Bangdiwala Ananta S AS   Kwizera Richard R   Kandole Tadeo Kiiza TK   Tugume Lillian L   Kiggundu Reuben R   Mpoza Edward E   Nuwagira Edwin E   Williams Darlisha A DA   Lofgren Sarah M SM   Abassi Mahsa M   Musubire Abdu K AK   Cresswell Fiona V FV   Rhein Joshua J   Muzoora Conrad C   Hullsiek Kathy Huppler KH   Boulware David R DR   Meya David B DB  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20190501 12


<h4>Background</h4>Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal meningitis if untreated. The progression and timing from asymptomatic infection to cryptococcal meningitis is unclear. We describe a subpopulation of individuals with neurologic symptomatic cryptococcal antigenemia but negative cerebral spinal fluid (CSF) studies.<h4>Methods</h4>We evaluated 1201 human immunodeficiency virus-seropositive individuals hospitalized with suspected meningitis in K  ...[more]

Similar Datasets

| S-EPMC10061560 | biostudies-literature
| S-EPMC7755087 | biostudies-literature
| S-EPMC6007269 | biostudies-literature
| S-EPMC9734559 | biostudies-literature
| S-EPMC11288378 | biostudies-literature
| S-EPMC4527410 | biostudies-literature
| S-EPMC4390200 | biostudies-literature
| S-EPMC5388270 | biostudies-literature
| S-EPMC5008555 | biostudies-other
| S-EPMC6125572 | biostudies-literature